期刊
THERAPEUTIC ADVANCES IN MUSCULOSKELETAL DISEASE
卷 14, 期 -, 页码 -出版社
SAGE PUBLICATIONS LTD
DOI: 10.1177/1759720X221090297
关键词
disease-modifying drugs; DMOADs; endotype; intra-articular therapy; osteoarthritis
类别
资金
- National Health and Medical Research Council (NHMRC) Investigator Grant
- Presidential Scholarship of Myanmar
Current management of osteoarthritis is mainly palliative with a need for effective treatment. Attempts to discover disease-modifying drugs have so far been unsuccessful. This review discusses repurposed drugs and investigational agents in clinical trials, and offers insights into recent failures, promising findings, novel methodologies, and regulatory challenges.
In spite of a major public health burden with increasing prevalence, current osteoarthritis (OA) management is largely palliative with an unmet need for effective treatment. Both industry and academic researchers have invested a vast amount of time and financial expense to discover the first diseasing-modifying osteoarthritis drugs (DMOADs), with no regulatory success so far. In this narrative review, we discuss repurposed drugs as well as investigational agents which have progressed into phase II and III clinical trials based on three principal endotypes: bone-driven, synovitis-driven and cartilage-driven. Then, we will briefly describe the recent failures and lessons learned, promising findings from predefined post hoc analyses and insights gained, novel methodologies to enhance future success and steps underway to overcome regulatory hurdles.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据